Niles N L, McCorkell S J, Woodhouse N J
Horm Res. 1987;25(3):152-9. doi: 10.1159/000180647.
Six male patients (aged 21-34 years) with isolated hypothalamic hypogonadism were given subcutaneous pulses of gonadotrophin-releasing hormone every 90 min for 14-74 weeks. The therapy produced an increase in testicular volume (4 patients) and a rise in serum luteinizing hormone, follicle-stimulating hormone, and testosterone levels in every patient. Motile sperm developed in 3 patients after a mean of 17 weeks, but were not seen in other patients who were less sexually developed after a mean of 31 weeks of therapy. Computerized tomography scans of the pituitary fossa revealed an empty sella in 4 patients and a partially empty sella in 2. Subcutaneous pulsing of gonadotrophin-releasing hormone is a simple and safe way of inducing spermatogenesis, but it is more likely to be successful in patients whose pubertal development is otherwise near completion. Previous human chorionic gonadotrophin and/or testosterone treatment does not interfere with and may benefit subsequent gonadotrophin-releasing hormone therapy.
对6名患有孤立性下丘脑性性腺功能减退的男性患者(年龄21 - 34岁),每90分钟皮下注射一次促性腺激素释放激素,持续14 - 74周。治疗使4名患者的睾丸体积增大,每名患者的血清黄体生成素、卵泡刺激素和睾酮水平均升高。平均17周后,3名患者产生了活动精子,但在平均接受31周治疗后性发育较差的其他患者中未见到活动精子。垂体窝的计算机断层扫描显示,4名患者为空蝶鞍,2名患者为部分空蝶鞍。皮下脉冲式注射促性腺激素释放激素是诱导精子发生的一种简单且安全的方法,但在青春期发育接近完成的患者中更有可能成功。先前的人绒毛膜促性腺激素和/或睾酮治疗不会干扰后续的促性腺激素释放激素治疗,反而可能有益。